Palabras clave
FAS
FASLG
Linfoproliferación
Autoinmunidad
Resumen
El síndrome linfoproliferativo autoinmune (ALPS, autoimmune lymphoproliferative syndrome) es un error innato de la inmunidad, resultado de un grupo heterogéneo de alteraciones en los genes que regulan el fenómeno de apoptosis. Se manifiesta típicamente en los primeros años de vida. Las manifestaciones clínicas más comunes son la expansión linfoide con linfadenopatía, esplenomegalia y hepatomegalia, enfermedad autoinmune con citopenias, incluyendo trombocitopenia y anemia hemolítica, así como linfoma. Las anomalías de laboratorio que facilitan el diagnóstico de ALPS incluyen presencia de células alfa-beta T doble negativas, niveles elevados de interleucina 10, vitamina B12 en sangre y apoptosis defectuosa mediada por FAS en ensayo in vitro. El tratamiento de ALPS se centra en tres aspectos: el tratamiento de las manifestaciones de la enfermedad, la prevención y tratamiento de las complicaciones y el tratamiento curativo (trasplante de células progenitoras hematopoyéticas [TCPH]). Se sugiere el uso de tratamiento inmunosupresor solo para las complicaciones graves de la linfoproliferación o manifestaciones autoinmunes concomitantes. La esplenectomía no se recomienda para las manifestaciones autoinmunes en pacientes con ALPS. El TCPH se reserva para pacientes seleccionados. La tasa de supervivencia a 50 años se estima en 85 % para los pacientes con deficiencia de FAS.
Referencias
Worth A, Thrasher AJ, Gaspar HB. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Hematol. 2006;133(2):124-140. DOI: 10.1111/j.1365-2141.2006.05993.x
International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161-1178. DOI: 10.1016/j.jaci.2009.10.013
Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatrics. 1967;70(6):891-899. DOI: 10.1016/s0022-3476(67)80262-2
Seif AE, Manno CS, Sheen C, Grupp SA, Teachey D. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood. 2010;115(11):2142-2145. DOI: 10.1182/blood-2009-08-239525
Stepensky P, Rensing-Ehl A, Gather R, Revel-Vilk S, Fischer U, Nabhani S, et al. Early-onset Evans syndrome, immunodeficiency, and premature immunosenescence associated with tripeptidyl-peptidase II deficiency. Blood. 2015;125(5):753-761. DOI: 10.1182/blood-2014-08-593202
Bleesing JJ. Autoimmune lymphoproliferative syndrome: a genetic disorder of abnormal lymphocyte apoptosis. Immunol Allergy Clin North Am. 2002;22:339-355. Disponible en: https://www.immunology.theclinics.com/article/S0889-8561(01)00011-X/abstract
Bleesing JJ, Fleisher TA, Puck JM, et al. Autoimmune lymphoproliferative syndrome. En: Stiehm RE, Ochs HD, Winkelstein JA, Rich E (editores). Immunologic disorders of infant and children. EE. UU.: Elsevier; 2004.
Rieux-Laucat F, Blachère S, Danielan S, De Villartay JP, Oleastro M, Solary E, et al. Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations. Blood. 1999;94(8):2575-2582.
Rieux-Laucat F, Le Diest F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268(5215):1347-1349. DOI: 10.1126/science.7539157
Rieux-Laucat F. Le syndrome lymphoprilifératif avec auto-immunité. Un défaut herité ou acquis d´apoptose lymphocitaire. Med Sci. 2006;22(6-7):645-649. DOI: 10.1051/medsci/20062267645
Le Deist F, Emile JF, Riex-Laucat F, Benkerrou M, Roberts I, Brousse N, et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet. 1996;348(9029):719-723. DOI: 10.1016/S0140-6736(96)02293-3
Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, et al. Clinical, Immunologic and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89(4):1341-1347.
Oliveira JB, Bidere N, Niemela JE, Zheng L, Sakai K, Nix CP, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA. 2007;204(21):8953-8958. DOI: 10.1073/pnas.0702975104
Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur AM, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med. 2004;351(14):1409-1418. DOI: 10.1056/NEJMoa040036
Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood. 2011;118(22):5741-5751. DOI: 10.1182/blood-2011-07-325217
Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, et al. Inherited HUMAN Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98(1):47-58. DOI: 10.1016/S0092-8674(00)80605-4
Rieux-Laucat F, Magérus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. J Clin Immunol. 2018;38(5):558–568. DOI:10.1007/s10875-018-0523-x
Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996;98(5):1107-113. DOI: 10.1172/JCI118892
Kasahara Y, Wada T, Niida Y, Yachie A, Seki H, Ishida Y, et al. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. Int Immunol. 1998;10(2):195-202. DOI: 10.1093/intimm/10.2.195
van der Burg M, de Groot R, Comans-Bitter WM, den Hollander JC, Hooijkaas H, Neijens HJ, et al. Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant recessive disease? Pediatr Res. 2000;47(3):336-343. DOI: 10.1203/00006450-200003000-00009
Grombaek K, Dalby T, Zeuthen J, et al. The V4101 (G1228A) variant of caspase-10 gene is a common polymorphism of the Danish populations. Blood. 2000;95:2184-2185.
Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, et al. Pleiotropic defects in human lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419(6905):395-399. DOI: 10.1038/nature01063
Lambotte O, Neven B, Galicier L, Magerus-Chatinet A, Schleinitz N, Hermine O, et al. Diagnosis of autoimmune lymphoproliferative syndrome caused by FAS deficiency in adults. Haematologica. 2012;98(3):389-392. DOI: 10.3324/haematol.2012.067488
Hansford JR, Pal M, Poplawski N, Haan E, Boog B, Ferrante A, et al. In utero and early postnatal presentation of autoimmune lymphoproliferative syndrome in a family with a novel FAS mutation. Haematologica. 2013;98(4):e-38-e-39. DOI:10.3324/haematol.2012.070524
Jackson CE, Puck JM. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr Opin Pediatr. 1999;11(6):521-527. DOI: 10.1097/00008480-199912000-00009
Speckman C, Rohr J, Ehl S. Genetic disorders of immune regulation in primary immunodeficiency diseases. Monatsschr Kinderheilkd. 2009;157:878. DOI: 10.1007/s00112-009-1988-8
Rudman-Spergel, A, Walkovich K, Price S, Niemela JE, Wright D, Fleisher TA, et al. Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis. Pediatrics. 2013;132(5):e1440-e1444. DOI: 10.1542/peds.2012-2748
Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH, et al. Unmasking Evans syndrome: T cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105(6):2443-2448. DOI: 10.1182/blood-2004-09-3542
Seif A, Manno C, Grupp S, et al. Testing Patients with Evans syndrome for the autoimmune lymphoproliferative syndrome (ALPS): results of a large multi-institutional clinical trial (ASPHO supplement). Pediatr Blood Cancer. 2008;50:S22-S23.
Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rösen-Wolff A, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98(1):194-200. DOI: 10.1182/blood.v98.1.194
Russell TB, Kurre P. Double negative T cells are non-ALPS-specific markers of immune dysregulation found in patients with aplastic anemia. Blood. 2010;116(23):5072-5073. DOI: 10.1182/blood-2010-09-306910
Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from 2009 NIH International Workshop. Blood. 2010;116(14):e35-e40. DOI: 10.1182/blood-2010-04-280347
Bowen AR, Dowdell KC, Dale JK, Drake SK, Fleisher TA, Hortin GL, et al. Elevated vitamin B12 levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorrin in lymphocytes. Clin Biochem. 2012;45(6):490-492. DOI: 10.1016/j.clinbiochem.2012.01.016
Minemura H, Ikeda K, Tanino Y, Hashimoto Y, Nikaido T, Fukuhara A, et al. Multicentric Castleman’s disease with impaired lymphocytic apoptosis. Allergology Int. 2015;64(1):112-114. DOI: 10.1016/j.alit.2014.08.009
Teachey, DT. Targeting cytokines in ALPS: it’s FAShionable. Blood. 2014;123(8):1116-1118. DOI: 10.1182/blood-2014-01-546713
Barzaghi F, Minniti F, Mauro M, et al. ALPS-like phenotype caused by ADA2 deficiency rescued by allogeneic hematopoietic stem cell transplantation. Front Immunol. 2019;9:2767. DOI: 10.3389/fimmu.2018.02767
Fernández KS, Antony R, Kumar A. Patients with “ALPS-like phenotype” diagnosed with immune dysregulation due to LRBA deficiency. Pediatr Blood Cancer. 2019;66(3):e27558. DOI: 10.1002/pbc.27558
Schipp C, Schlütermann D, Hönscheid A, Nabhani S1, Höll J, Oommen PT, et al. EBV negative lymphoma and autoimmune lymphoproliferative syndrome like phenotype extend the clinical spectrum of primary immunodeficiency caused by STK4 deficiency. Front Immunol. 2018;9:2400. DOI: 10.3389/fimmu.2018.02400
Takagi M, Ogata S, Ueno H, Yoshida K, Yeh T, Hoshino A, et al. Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2017;139(6):1914-1922. DOI: 10.1016/j.jaci.2016.09.038
Teachey DT, Obzut UA, Axsom K, Choi JK, Goldsmith KC, Hall J, et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. 2006;108(6):1965-1971. DOI: 10.1182/blood-2006-01-010124
Rieux-Laucat, F., Magérus-Chatinet, A., & Neven, B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. J Clin Immunol. 2018;38(5):558-568. DOI: 10.1007/s10875-018-0523-x
Völkl S, Rensing-Ehl A, Allgäuer A, Schreiner E, Lorenz MR, Rohr J, et al. Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood. 2016;128(2):227-238. DOI: 10.1182/blood-2015-11-685024
Klemann C, Esquivel M, Megens-Ohetinet A, Lorenz MR, Fuchs I, Neveux N, et al. Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome. Haematologica. 2017;102(2):e52-e56. DOI: 10.3324/haematol.2016.153411
Shah S, Wu E, Rao VK, Tarrant TK. Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr Allergy Asthma Rep. 2014;14(9):462. DOI: 10.1007/s11882-014-0462-4
Rao VK, Price S, Perkins K, Aldridge P, Teller J, Davis J, et al. Use of mycophenolate mofetil in children with chronic, refractory immune cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009;52(6):697.
Heelan BT, Tormey V, Amlot P, Payne E, Mehta A, Webster AD. Effect of anti CD20 (rituximab) on resistant thrombocytopenia in autoinmune lymphoproliferative syndrome. Br J Haematol. 2002;118(4):1078-1081. DOI: 10.1046/j.1365-2141.2002.03753.x
Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F, et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am J Hematol. 2006;81(2):81-85. DOI: 10.1002/ajh.20523
Bleesing JJ. Autoimmune lymphoproliferative syndrome (ALPS). Curr Pharm Des. 2003;9:265.
Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol. 2003;15(3):325-331. DOI: 10.1016/s0952-7915(03)00042-6
van der Werff-Ten-Bosch J, Otten J, Thielemans K. Autoimmune lymphoproliferative syndrome type III: an indefinite disorder. Leuk Lymphoma. 2001;41(1-2):55-65. DOI: 10.3109/10428190109057954
van der Werff-Ten-Bosch J, Schotte P, Ferster A, Azzi N, Boehler T, Laurey G, et al. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol. 2002;117(2):176-188. DOI: 10.1046/j.1365-2141.2002.03357.x
Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005; 129:534.
Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009;52(7):847-852. DOI: 10.1002/pbc.21965
Dimopoulou MN, Gandhi S, Ghevaert C, Chakraverty R, Fielding A, Webster D, et al. Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion. Bone Marrow Transplant. 2007;40(6):605-606. DOI: 10.1038/sj.bmt.1705775
Sleight BJ, Prasad VS, DeLaat C, Steele P, Ballard E, Arceci RJ, et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant. 1998;22(4):375-380. DOI: 10.1038/sj.bmt.1701306
Caminha I, Fleisher T, Hornung RL, Dale JK, Niemela JE, Price S, et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy and Clin Immunol. 2010;125(4):946-949. DOI: 10.1016/j.jaci.2009.12.983
Holler N, Tarvidel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. Two adjacent trimetric Fas ligands are required for Fas signaling and formation of a death inducing signaling complex. Mol Cell Biol. 2003;23(4):1428-1440. DOI: 10.1128/mcb.23.4.1428-1440.2003
Teachey DT, Greiner R, Seif A, Attiyeh E, Bleessing J, Choi J, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145(1):101-106. DOI: 10.1111/j.1365-2141.2009.07595.x
Neven B, Magerus-Chatinet A, Florkin B, Gobert D, Lambotte O, de Somer L, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118(18):4798. DOI: 10.1182/blood-2011-04-347641
Teachey DT. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr. 2012;24(1):1-8. DOI: 10.1097/MOP.0b013e32834ea739.
Russell TB, Kurre P. Double-negative T cells are non-ALPS-specific markers of immune dysregulation found in patients with aplastic anemia. Blood. 2010;116(23):5072-5073. DOI: 10.1182/blood-2010-09-306910
Pace R, Vinh DC. Autoimmune lymphoproliferative syndrome and Epstein-Barr virus-associated lymphoma: an adjunctive diagnostic role for monitoring EBV viremia? Case Reports Immunology. 2013;2013:245893. DOI: 10.1155/2013/245893
Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol. 2010;148(2):205-216. DOI: 10.1111/j.1365-2141.2009.07991.x
Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145(1):101. DOI: 10.1111/j.1365-2141.2009.07595.x
Oliveira VD, Zankl H, Rath T. Mutagenic and cytotoxic effects of immunosuppressive drugs on human lymphocyte cultures. Exp Clin Transplant. 2004;2(2):273-279. Disponible en: http://www.ectrx.org/forms/ectrxcontentshow.php?year=2004&volume=2&issue=2&supplement=0&makale_no=0&spage_number=273&content_type=FULL%20TEXT
Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol. 2013;37(6):602-612. DOI: 10.1159/000351648
Miano M, Calvillo M, Palmisani E, Fioredda F, Micalizzi C, Svahn J, et al. Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children. Br J Haematol. 2014;167(4):571-574. DOI: 10.1111/bjh.13010
Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17-28. DOI: 10.1182/blood-2015-07-657981
Wei A, Cowie T. Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7 + 2 T > C) affecting the Fas gene. Eur J Haematol. 2007;79(4):363-366. DOI: 10.1111/j.1600-0609.2007.00924.x
Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009;52(7):847-852. DOI: 10.1002/pbc.21965
Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, et al. Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant. 2014;20(10):1654-1659. DOI: 10.1016/j.bbmt.2014.06.032
Benkerrou M, Le Deist F, de Villartay JP, Caillat-Zucman S, Rieux-Laucat F, Jabado N, et al. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Eur J Immunol. 1997;27(8):2043-2047. DOI: 10.1002/eji.1830270831
Boggio E, Aricò M, Melensi M, Dianzani I, Ramenghi U, Dianzani U, et al. Mutation of FAS, XIAP, and UNC13D genes in a patient with a complex lymphoproliferative phenotype. Pediatrics. 2013;132(4):e1052-e1058. DOI: 10.1542/peds.2012-1838
Aricò M, Boggio E, Cetica V, Melensi M, Orilieri E, Clemente N, et al. Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome. PLoS One. 2013;8(7):e68045.
Neven B, Bruneau J, Stolzenberg MC, Meyts I, Magerus-Chatinet A, Moens L, et al. Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. Blood. 2014;124(10):1597-1609. DOI: 10.1182/blood-2014-02-553834
Magerus-Chatinet A, Neven B, Stolzenberg MC, Daussy C, Arkwright PD, Lanzarotti N, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest. 2011;121(1):106-112. DOI: 10.1172/JCI43752
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2020 Revista Alergia México